Supernus Pharmaceuticals (SUPN) Competitors $45.46 -1.20 (-2.57%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$45.47 +0.01 (+0.02%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SUPN vs. JAZZ, CORT, PRGO, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Supernus Pharmaceuticals vs. Its Competitors Jazz Pharmaceuticals Corcept Therapeutics Perrigo Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Supernus Pharmaceuticals (NASDAQ:SUPN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Do analysts recommend SUPN or JAZZ? Supernus Pharmaceuticals presently has a consensus target price of $43.00, indicating a potential downside of 5.41%. Jazz Pharmaceuticals has a consensus target price of $178.67, indicating a potential upside of 41.62%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supernus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Jazz Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is SUPN or JAZZ more profitable? Supernus Pharmaceuticals has a net margin of 9.70% compared to Jazz Pharmaceuticals' net margin of -9.91%. Supernus Pharmaceuticals' return on equity of 14.22% beat Jazz Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Supernus Pharmaceuticals9.70% 14.22% 10.82% Jazz Pharmaceuticals -9.91%5.02%1.73% Does the media favor SUPN or JAZZ? In the previous week, Jazz Pharmaceuticals had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 14 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.38 beat Supernus Pharmaceuticals' score of 0.69 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 15 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has better valuation & earnings, SUPN or JAZZ? Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSupernus Pharmaceuticals$661.82M3.85$73.86M$1.1539.53Jazz Pharmaceuticals$4.07B1.88$560.12M-$6.73-18.75 Do institutionals and insiders believe in SUPN or JAZZ? 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, SUPN or JAZZ? Supernus Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. SummarySupernus Pharmaceuticals and Jazz Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.62B$4.46B$5.87B$10.13BDividend YieldN/A1.27%5.68%4.60%P/E Ratio39.5311.1374.5225.93Price / Sales3.8515.86537.17192.28Price / Cash11.197.2937.5660.44Price / Book2.423.3312.166.29Net Income$73.86M-$134.23M$3.28B$270.77M7 Day Performance-1.17%-1.56%0.87%3.88%1 Month Performance6.61%7.56%4.96%4.88%1 Year Performance46.13%37.23%60.74%26.01% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals2.5525 of 5 stars$45.46-2.6%$43.00-5.4%+47.1%$2.62B$661.82M39.53580Positive NewsInsider TradeJAZZJazz Pharmaceuticals4.5379 of 5 stars$129.85+0.3%$178.67+37.6%+18.5%$7.86B$4.07B-19.292,800News CoveragePositive NewsCORTCorcept Therapeutics4.7741 of 5 stars$71.23+2.7%$134.50+88.8%+104.1%$7.31B$675.04M63.04300News CoverageAnalyst ForecastInsider TradePRGOPerrigo4.8986 of 5 stars$22.31-1.5%$33.00+47.9%-18.0%$3.12B$4.37B-38.468,379News CoveragePositive NewsPCRXPacira BioSciences3.1871 of 5 stars$26.74+1.1%$30.83+15.3%+113.0%$1.19B$700.97M-9.62720Positive NewsNKTRNektar Therapeutics4.0754 of 5 stars$44.33+10.3%$88.33+99.3%+159.6%$764.17M$98.43M-5.04220Insider TradeHigh Trading VolumeOMEROmeros3.9662 of 5 stars$4.21+1.0%$18.00+327.6%+11.0%$283.79MN/A-2.00210Positive NewsASMBAssembly Biosciences3.4503 of 5 stars$23.32-2.1%$41.33+77.2%+21.1%$182.71M$28.52M-4.18100News CoverageShort Interest ↑CPIXCumberland Pharmaceuticals1.0021 of 5 stars$3.31flatN/A+164.6%$49.52M$42.07M-15.0580LLYEli Lilly and Company4.9979 of 5 stars$738.58+1.6%$950.17+28.6%-19.3%$688.27B$53.26B48.2747,000Trending NewsJNJJohnson & Johnson4.6908 of 5 stars$178.30-0.1%$176.29-1.1%+8.2%$429.72B$90.63B19.07138,100Trending NewsAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies JAZZ Alternatives CORT Alternatives PRGO Alternatives PCRX Alternatives NKTR Alternatives OMER Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SUPN) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SUPN Stock Alerts